Diagnosis of complement alternative pathway disorders

Kidney International

Volumn 89, Issue 2, 2016, Pages 278-288

  Angioi, Andrea ^a   Fervenza, Fernando C ^a   Sethi, Sanjeev ^a   Zhang, Yuzhou ^b   Smith, Richard J ^b   Murray, David ^a   Van Praet, Jens ^c   Pani, Antonello ^d   De Vriese, An S ^c  

^a Mayo Clinic College of Medicine   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c Department of Internal Medicine   (Belgium)

^d BROTZU HOSPITAL   (Italy)

Author keywords

alternative pathway; atypical hemolytic uremic syndrome; C3 glomerulonephritis; C3 glomerulopathy; classical pathway; complement; dense deposit disease; glomerulonephritis

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C3; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BIOCHEMICAL ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DISORDER; DIAGNOSTIC TEST; DISEASE MARKER; FUNCTIONAL ASSESSMENT; GENETIC ANALYSIS; GENETIC DISORDER; GLOMERULONEPHRITIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOREGULATION; KIDNEY BIOPSY; KIDNEY DISEASE; LABORATORY TEST; LASER MICRODISSECTION; MASS SPECTROMETRY; MEDICAL PRACTICE; NEPHROLOGIST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM DISEASES; KIDNEY DISEASES;

COMPLEMENT PATHWAY, ALTERNATIVE; HUMANS; IMMUNE SYSTEM DISEASES; KIDNEY DISEASES;

EID: 84961585340     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2015.12.003     Document Type: Short Survey

References (92)

1. S.J. Gou, J. Yuan, M. Chen, and et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis Kidney Int 83 2013 129 137
2. M. Noris, and G. Remuzzi Overview of complement activation and regulation Semin Nephrol 33 2013 479 492
3. J.M. Thurman, and V.M. Holers The central role of the alternative complement pathway in human disease J Immunol 176 2006 1305 1310
4. M. Botto, M. Kirschfink, P. Macor, and et al. Complement in human diseases: lessons from complement deficiencies Mol Immunol 46 2009 2774 2783
5. M.J. Walport Complement. Second of two parts N Engl J Med 344 2001 1140 1144
6. P.D. Stahl, and R.A. Ezekowitz The mannose receptor is a pattern recognition receptor involved in host defense Curr Opin Immunol 10 1998 50 55
7. C. Kemper, J.P. Atkinson, and D.E. Hourcade Properdin: emerging roles of a pattern-recognition molecule Annu Rev Immunol 28 2010 131 155
8. E. Goicoechea de Jorge, J.J. Caesar, T.H. Malik, and et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo Proc Natl Acad U S A 110 2013 4685 4690
9. C. Skerka, Q. Chen, V. Fremeaux-Bacchi, and et al. Complement factor H related proteins (CFHRs) Mol Immunol 56 2013 170 180
10. S.R. Cataland, V.M. Holers, S. Geyer, and et al. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP Blood 123 2014 3733 3738
11. Z. Prohaszka, L. Varga, and G. Fust The use of 'real-time' complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies Br J Haematol 158 2012 424 425
12. M. Petri Systemic Lupus International Collaborating Clinic (SLICC) SLICC Revision of the ACR Classification Criteria for SLE [abstract] Arthritis Rheum 60 2009 895
13. A. Berthe-Aucejo, M. Sacquepee, M. Fila, and et al. Blockade of alternative complement pathway in dense deposit disease Case Rep Nephrol 2014 2014 201568
14. M. Noris, M. Galbusera, S. Gastoldi, and et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy Blood 124 2014 1715 1726
15. D.W. Bowden, M. Rising, G. Akots, and et al. Homogeneous, liposome-based assay for total complement activity in serum Clin Chem 32 1986 275 278
16. S. Yamamoto, K. Kubotsu, M. Kida, and et al. Automated homogeneous liposome-based assay system for total complement activity Clin Chem 41 1995 586 590
17. S. Sethi, R.J. Smith, J.J. Dillon, and et al. C3 glomerulonephritis associated with complement factor B mutation Am J Kidney Dis 65 2015 520 521
18. M.A. Abrera-Abeleda, C. Nishimura, K. Frees, and et al. Allelic variants of complement genes associated with dense deposit disease J Am Soc Nephrol 22 2011 1551 1559
19. A.S. Grumach, and M. Kirschfink Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach Mol Immunol 61 2014 110 117
20. P. Sanchez-Corral, C. Gonzalez-Rubio, S. Rodriguez de Cordoba, and et al. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H Mol Immunol 41 2004 81 84
21. A.L. Stahl, F. Vaziri-Sani, S. Heinen, and et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation Blood 111 2008 5307 5315
22. M. Jozsi, S. Strobel, H.M. Dahse, and et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome Blood 110 2007 1516 1518
23. S.A. Johnson, J.M. Williams, S. Hakobyan, and et al. Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome: a pedigree revisited Mol Immunol 47 2010 1585 1591
24. A. Servais, L.H. Noel, L.T. Roumenina, and et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies Kidney Int 82 2012 454 464
25. S. Sethi, F.C. Fervenza, Y. Zhang, and et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement Kidney Int 83 2013 293 299
26. S. Sethi, F.C. Fervenza, Y. Zhang, and et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up Kidney Int 82 2012 465 473
27. J. Caprioli, M. Noris, S. Brioschi, and et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome Blood 108 2006 1267 1279
28. M. Noris, J. Caprioli, E. Bresin, and et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype Clin J Am Soc Nephrol 5 2010 1844 1859
29. L.M. Geerdink, D. Westra, J.A. van Wijk, and et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics Pediatr Nephrol 27 2012 1283 1291
30. E. Bresin, E. Rurali, J. Caprioli, and et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype J Am Soc Nephrol 24 2013 475 486
31. W.L. Robson, A.K. Leung, G.H. Fick, and et al. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome Nephron 62 1992 296 299
32. A.L. Lapeyraque, M. Malina, V. Fremeaux-Bacchi, and et al. Eculizumab in severe Shiga-toxin-associated HUS N Engl J Med 364 2011 2561 2563
33. M.P. Ruiz-Torres, F. Casiraghi, M. Galbusera, and et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies Thromb Haemost 93 2005 443 452
34. E.S. Reis, D.A. Falcao, and L. Isaac Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H Scand J Immunol 63 2006 155 168
35. T.E. Mollnes, T.S. Jokiranta, L. Truedsson, and et al. Complement analysis in the 21st century Mol Immunol 44 2007 3838 3849
36. Y. Yang, K. Lhotta, E.K. Chung, and et al. Complete complement components C4A and C4B deficiencies in human kidney diseases and systemic lupus erythematosus J Immunol 173 2004 2803 2814
37. S.F. Grant, H. Kristjansdottir, K. Steinsson, and et al. Long PCR detection of the C4A null allele in B8-C4AQ0-C4B1-DR3 J Immunol Methods 244 2000 41 47
38. Y. Zhang, C.M. Nester, B. Martin, and et al. Defining the complement biomarker profile of C3 glomerulopathy Clin J Am Soc Nephrol 9 2014 1876 1882
39. G.M. Naked, M.P. Florido, P. Ferreira de Paula, and et al. Deficiency of human complement factor I associated with lowered factor H Clin Immunol 96 2000 162 167
40. A. Richards, M.K. Liszewski, D. Kavanagh, and et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome Mol Immunol 44 2007 111 122
41. V. Fremeaux-Bacchi, E.A. Moulton, D. Kavanagh, and et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome J Am Soc Nephrol 17 2006 2017 2025
42. R. Norda, U. Schott, O. Berseus, and et al. Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma Vox Sang 102 2012 125 133
43. B. Teisner, I. Brandslund, N. Grunnet, and et al. Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation J Clin Lab Immunol 12 1983 63 67
44. K.N. Ekdahl, D. Norberg, A.A. Bengtsson, and et al. Use of serum or buffer-changed EDTA-plasma in a rapid, inexpensive, and easy-to-perform hemolytic complement assay for differential diagnosis of systemic lupus erythematosus and monitoring of patients with the disease Clin Vaccine Immunol 14 2007 549 555
45. S. Manzi, J.E. Rairie, A.B. Carpenter, and et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity Arthritis Rheum 39 1996 1178 1188
46. T.C. Wu, S. Yang, S. Haven, and et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura J Thromb Haemost 11 2013 1925 1927
47. Y. Zhang, N.C. Meyer, K. Wang, and et al. Causes of alternative pathway dysregulation in dense deposit disease Clin J Am Soc Nephrol 7 2012 265 274
48. F. Bu, N.C. Meyer, Y. Zhang, and et al. Soluble C5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome Am J Kidney Dis 65 2015 968
49. M. Reti, P. Farkas, D. Csuka, and et al. Complement activation in thrombotic thrombocytopenic purpura J Thromb Haemost 10 2012 791 798
50. J.N. George How I treat patients with thrombotic thrombocytopenic purpura: 2010 Blood 116 2010 4060 4069
51. T. Ono, J. Mimuro, S. Madoiwa, and et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure Blood 107 2006 528 534
52. T.C. Nguyen, A. Liu, L. Liu, and et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis Haematologica 92 2007 121 124
53. M. Uemura, Y. Fujimura, M. Matsumoto, and et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis Thromb Haemost 99 2008 1019 1029
54. A. Sanchez-Luceros, C.E. Farias, M.M. Amaral, and et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women Thromb Haemost 92 2004 1320 1326
55. P.M. Mannucci, M.T. Canciani, I. Forza, and et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor Blood 98 2001 2730 2735
56. S. Feng, S.J. Eyler, Y. Zhang, and et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome Blood 122 2013 1487 1493
57. S. Strobel, M. Zimmering, K. Papp, and et al. Anti-factor B autoantibody in dense deposit disease Mol Immunol 47 2010 1476 1483
58. L. Skattum, U. Martensson, and A.G. Sjoholm Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies J Intern Med 242 1997 455 464
59. A.S. Bomback, R.J. Smith, G.R. Barile, and et al. Eculizumab for dense deposit disease and C3 glomerulonephritis Clin J Am Soc Nephrol 7 2012 748 756
60. V. Fremeaux-Bacchi, L. Weiss, C. Demouchy, and et al. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity Nephrol Dial Transplant 9 1994 1747 1750
61. D.G. Williams, O. Kourilsky, L. Morel-Maroger, and et al. C3 breakdown by serum from patients with acute post-streptococcal nephritis Lancet 2 1972 360 361
62. C. Licht, S. Heinen, M. Jozsi, and et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II) Kidney Int 70 2006 42 50
63. R.E. Spitzer, A.E. Stitzel, and G.C. Tsokos Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis Clin Immunol Immunopathol 57 1990 10 18
64. A.T. Gewurz, S.M. Imherr, S. Strauss, and et al. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual Clin Exp Immunol 54 1983 253 258
65. F. Tedesco, P.A. Tovo, G. Tamaro, and et al. Selective C3 deficiency due to C3 nephritic factor in an apparently healthy girl Ric Clin Lab 15 1985 323 329
66. A. Karstorp C3 activator and hypocomplementaemia in a "healthy" woman Br Med J 1 1976 501 502
67. L. Halbwachs, M. Leveille, P. Lesavre, and et al. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme J Clin Invest 65 1980 1249 1256
68. M.R. Daha, H.M. Hazevoet, L.A. Vanes, and et al. Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus Immunology 40 1980 417 424
69. E.C. Miller, N.M. Chase, P. Densen, and et al. Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited Clin Immunol 145 2012 241 250
70. H. Ohi, and T. Yasugi Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN) Clin Exp Immunol 95 1994 316 321
71. R. Watson, S. Lindner, P. Bordereau, and et al. Standardisation of the factor H autoantibody assay Immunobiology 219 2014 9 16
72. M.A. Dragon-Durey, C. Loirat, S. Cloarec, and et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome J Am Soc Nephrol 16 2005 555 563
73. R.J. Smith, C.L. Harris, and M.C. Pickering Dense deposit disease Mol Immunol 48 2011 1604 1610
74. S. Sethi, F.C. Fervenza, Y. Zhang, and et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement Clin J Am Soc Nephrol 6 2011 1009 1017
75. S. Meri, V. Koistinen, A. Miettinen, and et al. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis J Exp Med 175 1992 939 950
76. F. Bridoux, E. Desport, V. Fremeaux-Bacchi, and et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 6 2011 2165 2174
77. S. Sethi, L. Zand, N. Leung, and et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy Clin J Am Soc Nephrol 5 2010 770 782
78. Bu F, Ghiringhelli Borsa N, Jones M, et al. High-throughput genetic testing for the thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol, in press.
79. F. Bu, T. Maga, N.C. Meyer, and et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome J Am Soc Nephrol 25 2014 55 64
80. M. Noris, C. Mele, and G. Remuzzi Podocyte dysfunction in atypical haemolytic uraemic syndrome Nat Rev Nephrol 11 2015 245 252
81. Barbour TD, Ruseva MM, Pickering MC. Update on C3 glomerulopathy [e-pub ahead of print]. Nephrol Dial Transplant. http://dx.doi.org/10.1093/ndt/gfu317.
82. A. Tortajada, S. Pinto, J. Martinez-Ara, and et al. Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance Kidney Int 81 2012 56 63
83. C.A. Castellani, M.G. Melka, A.E. Wishart, and et al. Biological relevance of CNV calling methods using familial relatedness including monozygotic twins BMC Bioinformatics 15 2014 114
84. J. Thusberg, A. Olatubosun, and M. Vihinen Performance of mutation pathogenicity prediction methods on missense variants Hum Mutat 32 2011 358 368
85. S. Richards, N. Aziz, S. Bale, and et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genet Med 17 2015 405 424
86. M. Heurich, R. Martinez-Barricarte, N.J. Francis, and et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk Proc Natl Acad Sci U S A 108 2011 8761 8766
87. S. Sethi, and F.C. Fervenza Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS) Semin Thromb Hemost 40 2014 416 421
88. M.C. Pickering, V.D. D'Agati, C.M. Nester, and et al. C3 glomerulopathy: consensus report Kidney Int 84 2013 1079 1089
89. S. Sethi, S.H. Nasr, A.S. De Vriese, and F.C. Fervenza C4d as a diagnostic tool in the diagnosis of proliferative glomerulonephritis J Am Soc Nephrol 26 2015 2852 2859
90. S. Sethi, J.D. Gamez, J.A. Vrana, and et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway Kidney Int 75 2009 952 960
91. M. Alberti, E. Valoti, R. Piras, and et al. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations Am J Transplant 13 2013 2201 2206
92. D. Landau, H. Shalev, G. Levy-Finer, and et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency J Pediatr 138 2001 412 417